Curis Lifesciences Limited CURISshare price and chart
Curis Lifesciences closed at ₹165.00 on 17 November 2026, down 0.60% on the day. The 52-week range is ₹83.60 to ₹234.75.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on CURIS
Real prices, every charge counted. Pick one or write your own.Curis Lifesciences develops, makes and distributes medicines, including tablets, capsules, liquid orals, creams, gels, ointments and sterile eye ointments, through contract manufacturing, loan licensing and its own brands, for customers in India and abroad.
Pharmaceuticals & Biotechnology
Tablets, capsules, liquid orals, ointments, eye ointments
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 17 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsShareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 3 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash rose by ₹3 Cr, after ₹2 Cr spent on plant and equipment.
The full numbersSales and net profit by financial year or by quarter.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.49 L cr | 41.0x | 5.0x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.85% |
| DIVISLAB Divi's Laboratories Limited | 2.93 L cr | 87.2x | 16.3x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.27% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.75 L cr | 77.9x | 9.6x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.82% |
| LAURUSLABS Laurus Labs Limited | 1.25 L cr | 93.6x | 20.7x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.09% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.20 L cr | 28.9x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.17 L cr | 41.6x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.57% |
| CIPLA Cipla Limited | 1.14 L cr | 39.5x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.92% |
| MANKIND Mankind Pharma Limited | 1.08 L cr | 48.3x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.03 L cr | 26.1x | 2.6x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.39% |
| LUPIN Lupin Limited | 90,173 cr | 17.3x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.91% |
| GLENMARK Glenmark Pharmaceuticals Limited | 74,679 cr | 51.5x | 6.7x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.09% |
| ALKEM Alkem Laboratories Limited | 62,443 cr | 30.2x | 4.2x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.01% |
| BIOCON Biocon Limited | 58,987 cr | 215.4x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 54,122 cr | 32.7x | - | - | - | - | 23.0% | +11.0% | 2.58% |
| GLAND Gland Pharma Limited | 53,307 cr | 43.1x | 5.0x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.62% |
| IPCALAB IPCA Laboratories Limited | 47,039 cr | 33.5x | 5.4x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 44,693 cr | 39.5x | 23.8x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.16% |
| EMCURE Emcure Pharmaceuticals Limited | 44,294 cr | 40.5x | 8.3x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 40,909 cr | 32.4x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.98% |
| SAILIFE Sai Life Sciences Limited | 37,978 cr | 100.5x | 14.1x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 32,931 cr | 80.3x | 6.4x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 32,677 cr | 74.4x | 17.6x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| PPLPHARMA Piramal Pharma Limited | 31,813 cr | - | 3.9x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| NEULANDLAB Neuland Laboratories Limited | 27,527 cr | 60.8x | 13.6x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| RUBICON Rubicon Research Limited | 27,450 cr | 84.1x | 19.4x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| APLLTD Alembic Pharmaceuticals Limited | 20,528 cr | 24.3x | 3.5x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.15% |
| GRANULES Granules India Limited | 19,762 cr | 27.6x | 3.0x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| ERIS Eris Lifesciences Limited | 18,530 cr | 26.0x | 4.5x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.54% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,189 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| SHILPAMED Shilpa Medicare Limited | 17,902 cr | 53.6x | 6.5x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.07% |
| ALIVUS Alivus Life Sciences Limited | 17,737 cr | 26.5x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.35% |
| PFIZER Pfizer Limited | 17,575 cr | 20.4x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,462 cr | 507.1x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 16,098 cr | 17.7x | 1.6x | 16.9% | 17.1% | 0.11 | 26.9% | -29.0% | 0.70% |
| CAPLIPOINT Caplin Point Laboratories Limited | 15,851 cr | 23.0x | 4.1x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.38% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,109 cr | 85.0x | 17.2x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.60% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,870 cr | 56.2x | 2.1x | 6.0% | 8.7% | 0.54 | 2.9% | +20.5% | 0.54% |
| CORONA CORONA Remedies Limited | 13,799 cr | 66.7x | 17.1x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.44% |
| MARKSANS Marksans Pharma Limited | 13,349 cr | 23.8x | 4.0x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.31% |
| CURIS Curis Lifesciences Limited | 133 cr | 16.9x | 2.6x | - | 15.5% | 0.39 | 10.2% | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.3 | -6.3 | -5.2 | +34.4 | -5.5 | -14.0 | +11.3 | +20.8 | +59.1 | -17.2 | -8.3 | · | +36.8% 11m |
| 2025 | · | · | · | · | · | · | · | · | · | · | · | -8.6 | -8.6% 1m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2026-03-06 | SIXTH SENSE SECURITIES PRIVATE LIMITED · bulk | BUY | 93,000 | ₹95.14 | ₹0.88 Cr |
| 2026-03-06 | RS SECURITIES · bulk | SELL | 93,000 | ₹95.05 | ₹0.88 Cr |
| 2026-01-05 | SS CORPORATE SECURITIES LIMITED · bulk | BUY | 64,000 | ₹129.55 | ₹0.83 Cr |
| 2026-01-05 | VINEY GROWTH FUND · bulk | SELL | 42,000 | ₹129.15 | ₹0.54 Cr |
| 2025-12-26 | SS CORPORATE SECURITIES LIMITED · bulk | BUY | 61,000 | ₹116.54 | ₹0.71 Cr |
| 2025-11-14 | PREETI BHAUKA · bulk | BUY | 1,20,000 | ₹146.10 | ₹1.75 Cr |
| 2025-11-14 | RADHU DEVELOPERS PRIVATE LIMITED · bulk | BUY | 53,000 | ₹143.00 | ₹0.76 Cr |
| 2025-11-14 | SACHIN KAPOOR · bulk | BUY | 50,000 | ₹146.10 | ₹0.73 Cr |
- Board outcomeOutcome of Board Meeting11 Nov 2026
Curis Lifesciences Limited has submitted to the Exchange, the standalone and consolidated financial results for the half year ended September 30, 2026.
- Press releasePress Release23 Jun 2026
Curis Lifesciences Limited has informed the Exchange regarding a press release dated Jun 23, 2026, titled "Press Release pertaining to audited financial results for the half year and yearended 31st March 2026".
- Board outcomeOutcome of Board Meeting30 May 2026
Curis Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 30, 2026 regarding considering and approving the Audited Standalone Financial Results of the company for the half year and year ended on March 31, 2026.
- Integrated Filing- Financial30 May 2026
Outcome of Board Meeting held on May 30, 2026 to consider and approve the Audited Standalone Financial Results of the company for the half year and year ended on March 31, 2026.
- Board outcomeOutcome of Board Meeting5 Dec 2025
Curis Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test CURIS. “Buy CURIS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free